Enterprise Value

203.7M

Cash

77.79M

Avg Qtr Burn

-13.86M

Short % of Float

0.16%

Insider Ownership

0.00%

Institutional Own.

0.21%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Elafibranor Details
Primary biliary cholangitis, Liver disease

Approved

Quarterly sales

VS-01 Details
Acute-on-Chronic liver failure, Liver disease

Phase 2

Data readout

Nitazoxanide (NTZ) Details
Non-alcoholic steatohepatitis , Acute-on-Chronic liver failure, Liver disease

Phase 2

Initiation

GNS561 Details
Liver disease, Cholangiocarcinoma

Phase 1b

Data readout

Elafibranor Details
Non-alcoholic steatohepatitis

Failed

Discontinued